S
Simon G. Gregory
Researcher at Duke University
Publications - 216
Citations - 50384
Simon G. Gregory is an academic researcher from Duke University. The author has contributed to research in topics: Single-nucleotide polymorphism & Gene. The author has an hindex of 54, co-authored 198 publications receiving 47130 citations. Previous affiliations of Simon G. Gregory include University of Helsinki & Wellcome Trust.
Papers
More filters
Posted ContentDOI
The Na+/K+ ATPase Regulates Glycolysis and Defines Immunometabolism in Tumors
Sydney M. Sanderson,Zhengtao Xiao,Amy J. Wisdom,Shree Bose,Maria V. Liberti,Michael A. Reid,Emily Hocke,Simon G. Gregory,David G. Kirsch,Jason W. Locasale +9 more
TL;DR: In vivo and metabolomic results provide evidence that altering energy demands can be used to regulate glycolysis with cell-type specific consequences in a multicellular environment of biomedical interest.
Journal ArticleDOI
Profiling serum neurofilament light chain and glial fibrillary acidic protein in primary progressive multiple sclerosis
James Giarraputo,Stephanie N Giamberardino,Stephanie Arvai,Sarah Maichle,Christopher Eckstein,L. Kristin Newby,Simon G. Gregory +6 more
TL;DR: The authors examined the utility of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) as biomarkers in primary progressive multiple sclerosis in context with clinical severity, progression, and treatment.
Journal ArticleDOI
Strategies for Genotype Generation
Simon G. Gregory,John W. Gilbert +1 more
TL;DR: As single‐nucleotide polymorphisms become the mainstay of genetic analyses, it is important that their source, distribution and de novo identification before understood before they are incorporated into genetic linkage and association analyses.
Journal ArticleDOI
Association of autism with induced or augmented childbirth.
Journal ArticleDOI
Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy.
TL;DR: The goal of this study was to determine the feasibility of DNA copy number and whole exome sequencing (WES) analysis of circulating tumor cells (CTCs) from men with mCRPC receiving enzalutamide.